Ascendis Pharma (ASND)
(Real Time Quote from BATS)
$143.44 USD
+3.87 (2.77%)
Updated Sep 17, 2024 01:00 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 181 - 200 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Positive TC-PTH/HP Topline Eliminates SoC, Further Validates TransCon Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
4Q/FY19, Timelines Unaffected by COVID-19 and TC-PTH Ph2 Topline Mid-April
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY19, Timelines Unaffected by COVID-19 and TC-PTH Ph2 Topline Mid-April
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Emerging Pharma: Upcoming Material Catalysts in Companies with Plenty of Cash
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Corporate Update and TransCon PTH Ph2 Topline Results End of March
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
PaTH Forward for TransCon PTH Expands Study Enrollment; Topline Data in Q1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Initiation of Phase 3 TC-hGH Clinical Study in China
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Somatrogon Ph3 Non-Inferior; Despite Competition We Remain Positive on TC-hGH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Thoughts on Competitor Data; We Remain Positive on TC-hGH Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L